Cetera Trust Company N.A bought a new position in Haemonetics Corporation (NYSE:HAE – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,670 shares of the medical instruments supplier’s stock, valued at approximately $350,000.
A number of other large investors have also bought and sold shares of the business. Elevation Point Wealth Partners LLC bought a new position in Haemonetics in the 2nd quarter valued at $224,000. Northwestern Mutual Wealth Management Co. acquired a new position in Haemonetics in the second quarter worth $44,000. Evolve Private Wealth LLC bought a new stake in shares of Haemonetics during the second quarter worth $355,000. William Blair Investment Management LLC bought a new stake in shares of Haemonetics during the second quarter worth $24,906,000. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Haemonetics in the second quarter valued at $542,000. 99.67% of the stock is currently owned by institutional investors.
Haemonetics Price Performance
Shares of HAE stock opened at $108.34 on Tuesday. The firm has a market cap of $4.93 billion, a price-to-earnings ratio of 53.11, a PEG ratio of 2.18 and a beta of 0.52. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $109.57. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. The stock has a 50-day moving average price of $82.32 and a 200 day moving average price of $68.81.
Analysts Set New Price Targets
A number of research analysts recently issued reports on HAE shares. Mizuho lifted their price target on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. BTIG Research increased their price objective on shares of Haemonetics from $96.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. JPMorgan Chase & Co. raised their price objective on shares of Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Barrington Research boosted their target price on shares of Haemonetics from $95.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 19th. Finally, Robert W. Baird upped their target price on shares of Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and a consensus price target of $97.56.
Read Our Latest Research Report on Haemonetics
About Haemonetics
Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.
Further Reading
- Five stocks we like better than Haemonetics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
